Milestone Pharmaceuticals has its first approved product on pharmacy shelves, and the latest quarter was the first full commercial period. CARDAMYST, a self-administered calcium-channel-blocker nasal spray for sudden attacks of paroxysmal supraventricular tachycardia, is the first Food and Drug Administration clearance of a PSVT therapy in more than three decades. The investment debate is not whether the molecule works in the label that regulators already granted. It is whether a launch that produced hundreds of prescriptions still converts those scripts into paid demand now that commercial coverage has finally moved.
Coverage sat near a quarter of commercially insured lives through June, so the company used copay support and denial conversion that management described as giving the script away. Product revenue for the quarter was $559 thousand. That implied capture is a few hundred of net proceeds a script, not a specialty-launch net price. After the period closed, UnitedHealthcare and other plans lifted covered commercial lives to about half. The tension is whether that coverage step changes paid mix in the second half, or whether one-time writers and access friction keep net sales thin while selling costs stay elevated.
Cash of $171 million funds operations into the latter half of next year on management's stated runway. Against that cash sit a royalty claim that already accretes at a high teens effective rate and senior secured convertibles due later this decade. The question the next two reporting periods resolve is whether paid CARDAMYST demand can grow fast enough to justify the launch cost base, or whether the equity remains a cash-funded option on a larger atrial-fibrillation label.